New Delhi: India’s fourth-largest information technology (IT) firm HCL Technologies Ltd. has tied up with global pharma company Eli Lilly to open a co-innovation laboratory in Singapore for developing technologies and improving operational efficiencies to enhance Eli Lilly’s global competitiveness, the company said in a statement.
The two companies will establish a framework for incubating ideas and concepts based on tangible business needs. They will track technology trends and create proofs of concept for applied solution frameworks. This will involve HCL leveraging technologies such as: cloud computing, automation, business analytics, enterprise mobility and so on combined with its domain expertise to create applications and solutions to support Eli Lilly’s global operations.
Co-innovation will help the two companies extend the scale and scope of external partnerships and alliances. These will then, in turn, bring new ideas in the form of technology and knowledge to the market.
HCL refused to give financial details of the proposed investment as it is in a silent period before its quarterly results.
The laboratory, which will act as a key component of Eli Lilly’s IT innovation strategy, was inaugurated by Michael C. Heim, senior vice president and chief information officer, Eli Lilly.
“We are delighted to launch this co-innovation lab with HCL which will serve as a centre for our company’s efforts to leverage IT to create competitive differentiators for our business. HCL’s domain expertise in the pharmaceutical industry and excellent track record in IT transformation make them an ideal partner on this journey, which we believe will ultimately bring benefits to the patients we serve,” Heim said.
The HCL-Eli Lilly Co-Innovation Lab will be housed in a 35,000 sq ft dedicated space in HCL’s Jurong Development Center in Singapore. HCL, which already has over 1,000 engineers at the facility, will work closely with the government of Singapore to ensure the lab becomes a global hub of IT innovation in the pharmaceutical industry. It will also be front-ending a close collaboration with educational and academic research centres across the globe to meet these objectives.
“This co-innovation lab will accelerate the pursuit of innovation led transformation by providing a collaborative environment and systematically cultivate new ideas and possibilities for Eli Lilly,” said Virender Aggarwal, president and head of the Asia-Pacific and the Middle East and Africa regions for HCL.
“We warmly welcome the decision by HCL and Eli Lilly to establish their co-innovation lab here. This illustrates Singapore’s value as a leading location for innovation to develop, prove and commercialize customized IT solutions for industry verticals such as pharmaceuticals,” said Yeoh Keat Chuan, assistant managing director, Singapore Economic Development Board.
HCL has also opened a Global Enterprise Mobility Lab recently in Singapore and continues to invest in the country.